Loading clinical trials...
Loading clinical trials...
Tegoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Based Bismuth Quadruple Therapy for First-Line Helicobacter Pylori Eradication: A Prospective, Randomized, Multicenter, Superiority Study (TATH-1)
Conditions
Interventions
Tegoprazan 50 mg, tablets, orally, qd
Esomeprazole 20mg BID
+3 more
Locations
1
China
Hangzhou first people's Hospital
Hangzhou, Zhejiang, China
Start Date
November 1, 2023
Primary Completion Date
September 30, 2025
Completion Date
October 31, 2025
Last Updated
January 16, 2026
NCT07537634
NCT07516262
NCT07335406
NCT07179159
NCT07293910
NCT07358130
Lead Sponsor
Zhang Xiaofeng,MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions